Home › neck
 

Keywords :   


Tag: neck

Ericsson, Huawei neck and neck in networks

2015-09-03 02:00:00| Total Telecom industry news

Mobile infrastructure revenues grow 2% to $11.4 billion in Q2, says IHS.

Tags: networks ericsson neck huawei

 

South Africa: How Your Cellphone Is Breaking Your Neck

2015-06-20 15:19:29| Footwear - Topix.net

The angle at which you hold your head when using your cell phone could affect the cervical spine and result in a condition known as 'text neck'. This is according to a study by New York based back surgeon, Dr Kenneth Hansraj.

Tags: your south africa south africa

 
 

AMD lifts embargo on the Radeon R9 Fury Xs performance, shows GPU competing neck and neck with Nvidias GTX 980 Ti

2015-06-18 22:52:39| Extremetech

AMD has lifted the embargo on its own benchmark results -- does the Radeon R9 Fury X have what it takes to challenge the GTX 980 Ti? The company says yes.

Tags: performance shows ti neck

 

New Findings Show Durable Anti-Tumor Activity with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status

2015-05-29 20:06:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Results from KEYNOTE-012, the First and Largest Study to Date of an Anti-PD-1 Therapy in Head and Neck Cancer, to be Presented at 2015 ASCO Annual Meeting KEYTRUDA Monotherapy Achieved Overall Response Rate of 25 Percent in Heavily Pre-treated Patients Merck is Advancing a Broad Head and Neck Clinical Program for KEYTRUDA with Five Clinical Trials, Across Multiple Lines of Therapy and in Combination with Other Agents KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: show advanced status head

 

Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer

2015-05-29 14:30:32| Merck.com - Product News

Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgens investigational oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Language: English read more

Tags: with support head studies

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »